References
- Green CA, Yeates D, Goldacre A, et al. Admission to hospital for bronchiolitis in England: trends over five decades, geographical variation and association with perinatal characteristics and subsequent asthma. Arch Dis Child. 2015. doi:10.1136/archdischild-2015-308723. Epub 2015 Sept 4.
- Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–2128.
- Widmer K, Griffin MR, Zhu Y, et al. Respiratory syncytial virus- and human metapneumovirus-associated emergency department and hospital burden in adults. Influenza Other Respi Viruses. 2014;8(3):347–352.
- Reed C, Chaves SS, Daily Kirley P, et al. Estimating influenza disease burden from population-based surveillance data in the United States. PLoS One. 2015;10(3):e0118369.
- Nenna R, Ferrara M, Nicolai A, et al. Viral load in infants hospitalized for respiratory syncytial virus bronchiolitis correlates with recurrent wheezing at thirty-six-month follow-up. Pediatr Infect Dis J. 2015;34(10):1131–1132.
- Blanken MO, Rovers MM, Molenaar JM, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013;368(19):1791–1799.
- Drysdale SB, Alcazar-Paris M, Wilson T, et al. Viral lower respiratory tract infections and preterm infants’ healthcare utilisation. Eur J Pediatr. 2015;174(2):209–215.
- Murray J, Saxena S, Sharland M. Preventing severe respiratory syncytial virus disease: passive, active immunisation and new antivirals. Arch Dis Child. 2014;99(5):469–473.
- PATH. PATH RSV vaccine snapshot July 2015 [Internet]. 2015. [cited 2015 Aug 1]. Available from: http://sites.path.org/vaccinedevelopment/files/2015/07/RSV-snapshot-July2015.pdf.
- Novavax. Novavax Announces Grant of Up to $89 Million to Support Development of RSV F Vaccine to Protect Infants Via Maternal Immunization [Internet]. 2015. [cited 2015 Oct 1]. Available from: http://ir.novavax.com/phoenix.zhtml?c=71178&p=irol-newsArticle&ID=2091284.
- Rivera CA, Gómez RS, Díaz RA, et al. Novel therapies and vaccines against the human respiratory syncytial virus. Expert Opin Investig Drugs. 2015;1–18. Epub 2015 Oct 12.
- Kapikian AZ, Mitchell RH, Chanock RM, et al. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol. 1969;89(4):405–421.
- Munoz FM. Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy? Curr Opin Infect Dis. 2015;28(3):221–224.
- Murray J, Bottle A, Sharland M, et al. Risk factors for hospital admission with RSV bronchiolitis in England: a population-based birth cohort study. PLoS One. 2014;9(2):e89186.
- Nyiro JU, Sande C, Mutunga M, et al. Quantifying maternally derived respiratory syncytial virus specific neutralising antibodies in a birth cohort from coastal Kenya. Vaccine. 2015;33(15):1797–1801.
- Glenn GM, Fries LF, Thomas DN, et al. A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbreaing age. J Infect. 2015. doi:10.1093/infdis/jiv406. Epub 2015 Aug 10.
- Munywoki PK, Koech DC, Agoti CN, et al. The source of respiratory syncytial virus infection in infants: a household cohort study in rural Kenya. J Infect Dis. 2014;209:1685–1692.
- Kiti MC, Kinyanjui TM, Koech D, et al. Quantifying age-related rates of social contact using diaries in a rural coastal population of Kenya. PLoS One. 2014;9(8):e104786.
- Régnier SA. Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine. Vaccine. 2013;31(40):4347–4354.
- Meijboom MJ, Rozenbaum MH, Benedictus A, et al. Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in the Netherlands. Vaccine. 2012;30(31):4691–4700.